These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32267807)

  • 41. Identifying Barriers to Buprenorphine Treatment for Patients with Opioid Use Disorder Among Anesthesiologists and Pain Practitioners: A Survey Study.
    John S; Boorman DW; Potru S
    J Addict Med; 2023 Mar-Apr 01; 17(2):e94-e100. PubMed ID: 36001078
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 43. Opioid use disorder: current trends and potential treatments.
    Lee YK; Gold MS; Blum K; Thanos PK; Hanna C; Fuehrlein BS
    Front Public Health; 2023; 11():1274719. PubMed ID: 38332941
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design and methods of a multi-site randomized controlled trial of an integrated care model of long-acting injectable buprenorphine with infectious disease treatment among persons hospitalized with infections and opioid use disorder.
    Seval N; Frank CA; Litwin AH; Roth P; Schade MA; Pavlicova M; Levin FR; Brady KT; Nunes EV; Springer SA
    Contemp Clin Trials; 2021 Jun; 105():106394. PubMed ID: 33838307
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preliminary attitudes on medications for opioid use disorders (MOUDs) in Southeastern Switzerland and New York City.
    Castillo F; Scalise D; Hernandez D; Gupta R; Basaraba CN; Corbeil T; Comer SD; Schneeberger AR
    J Addict Dis; 2023; 41(1):91-97. PubMed ID: 35451354
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment Outcomes Among Black Adults Receiving Medication for Opioid Use Disorder.
    Parlier-Ahmad AB; Pugh M; Martin CE
    J Racial Ethn Health Disparities; 2022 Aug; 9(4):1557-1567. PubMed ID: 34254271
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adverse effects of regulation on buprenorphine prescribing and its impact on the treatment of opioid use disorder.
    Strickland DM; Sorboro J
    J Opioid Manag; 2021; 17(7):133-139. PubMed ID: 34520034
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnosis and Management of Opioid Use Disorder in Hospitalized Patients.
    Herscher M; Fine M; Navalurkar R; Hirt L; Wang L
    Med Clin North Am; 2020 Jul; 104(4):695-708. PubMed ID: 32505261
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Medication-Assisted Treatment Considerations for Women with Opiate Addiction Disorders.
    Jacobs AA; Cangiano M
    Prim Care; 2018 Dec; 45(4):731-742. PubMed ID: 30401353
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
    Jones CM; McCance-Katz EF
    Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Buprenorphine therapy for opioid addiction in rural Washington: the experience of the early adopters.
    Quest TL; Merrill JO; Roll J; Saxon AJ; Rosenblatt RA
    J Opioid Manag; 2012; 8(1):29-38. PubMed ID: 22479882
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Linking MATTERS: Barriers and Facilitators to Implementing Emergency Department-Initiated Buprenorphine-Naloxone in Patients with Opioid Use Disorder and Linkage to Long-Term Care.
    Sokol R; Tammaro E; Kim JY; Stopka TJ
    Subst Use Misuse; 2021; 56(7):1045-1053. PubMed ID: 33825669
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Survey of Barriers and Facilitators to Prescribing Buprenorphine and Clinician Perceptions on the Drug Addiction Treatment Act of 2000 Waiver.
    Lanham HJ; Papac J; Olmos DI; Heydemann EL; Simonetti N; Schmidt S; Potter JS
    JAMA Netw Open; 2022 May; 5(5):e2212419. PubMed ID: 35552721
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improving access to care via psychiatric clinical pharmacist practitioner collaborative management of buprenorphine for opioid use disorder.
    Pals H; Bratberg J
    J Am Pharm Assoc (2003); 2022; 62(4):1422-1429. PubMed ID: 35365405
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of buprenorphine for addiction treatment: perspectives of addiction specialists and general psychiatrists.
    Thomas CP; Reif S; Haq S; Wallack SS; Hoyt A; Ritter GA
    Psychiatr Serv; 2008 Aug; 59(8):909-16. PubMed ID: 18678689
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Beyond Buprenorphine: Models of Follow-up Care for Opioid Use Disorder in the Emergeny Department.
    Martin A; Butler K; Chavez T; Herring A; Wakeman S; Hayes BD; Raja A
    West J Emerg Med; 2020 Nov; 21(6):257-263. PubMed ID: 33207174
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prescribing Practices of Nurse Practitioners and Physician Assistants Waivered to Prescribe Buprenorphine and the Barriers They Experience Prescribing Buprenorphine.
    Andrilla CHA; Jones KC; Patterson DG
    J Rural Health; 2020 Mar; 36(2):187-195. PubMed ID: 31650634
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expert Panel Consensus on Management of Advanced Cancer-Related Pain in Individuals With Opioid Use Disorder.
    Merlin JS; Khodyakov D; Arnold R; Bulls HW; Dao E; Kapo J; King C; Meier D; Paice J; Ritchie C; Liebschutz JM
    JAMA Netw Open; 2021 Dec; 4(12):e2139968. PubMed ID: 34962565
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Development and Implementation of a Hospitalist-Directed Addiction Medicine Consultation Service to Address a Treatment Gap.
    Calcaterra SL; McBeth L; Keniston AM; Burden M
    J Gen Intern Med; 2022 Apr; 37(5):1065-1072. PubMed ID: 34013473
    [TBL] [Abstract][Full Text] [Related]  

  • 60. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
    Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
    Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.